PubRank

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Clinical Trial ID NCT00617669

PubWeight™ 22.04‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00617669

Top papers

Rank Title Journal Year PubWeight™‹?›
1 G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011 3.31
2 Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011 2.20
3 Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013 1.95
4 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
5 Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012 1.47
6 Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013 1.40
7 Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011 1.31
8 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
9 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
10 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
11 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
12 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
13 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
14 Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013 0.87
15 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
16 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
17 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
Next 100